Comparative Effects of Two Oral Antiseptics Used as an Adjuvant in the Treatment of Periodontitis

Inclusion Criteria: * Consenting patients with at least 6 evaluable teeth in each quadrant, including minimum 1 molar and 1 premolar. * Generalized stage II-III periodontitis patients. * Baseline BOP \> 25%. * No known allergy or adverse effects to CHX or CPC * Non-smokers, non-orthodontic patients, no concurrent or past antibiotics/medication known to affect periodontal status (i.e. calcium antagonists, phenytoin)/anti-inflammatory therapy (i.e. NASIDs) in the last 3 months, pregnant/breastfeeding, compliance to study procedures. * ASA class I-II patients. * Either non-diabetic or with controlled diabetes (HbA1C\<7). * Normal/Elevated blood pressure (AHA - Systolic \<130mmHg; Diastolic \<80mmHg). * No radiation/chemotherapy in the past 5 years * No immunosuppression including drug induced immunosuppression. * No participation in other clinical studies in the last 4 weeks. * No administration of CHX or CPC in the last 3 months * No periodontal treatment in the last 3 months. Exclusion Criteria: * Unable to provide written consent. * Non-compliant study procedures. * Patients with medical (including psychiatric) and pharmacotherapeutic histories that, in the investigator's opinion, may compromise the protocol. * Patients requiring antibiotics prophylaxis for dental procedures. * Patients with self-reported pregnancy or patients who are breastfeeding. * Patients with history of use of systemic antibiotics, in combination with any form of periodontal treatment, within the past 3 months. * Patients with uncontrolled endocrine disease. * Patients who are not compliant with the review protocol, leading to deviation of more than 1 week. * Patients requiring the admission of systemic antibiotics, in combination with any form of dental treatment, during the study period.